This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry

Candidates Against Warfarin II-41

A Comparative Study of Heparin Against Angiomax II-41

A Comparative Study of Arixtra Against UFH and LMWH II-41

A Comparative Study of Angiomax Against UFH and LMWH II-41



Indications for Anticoagulant Use II-42

Venous/DVT Thrombosis Indications II-42

Desired Anticoagulant Qualities for DVT Indications II-42

Venous Thromboembolism II-42

Deep Vein Thrombosis II-42

Pulmonary Embolism II-44

Orthopedic (Hip or Knee Replacement) Surgery II-45

General Surgery II-46

Cancer II-46

Arterial Thrombosis Indications II-47

Arterial Thrombosis II-47

Acute Coronary Syndromes II-47

Atrial Fibrillation II-48

Unstable Angina II-49

List of Approved Anticoagulants for Unstable Angina II-50

Myocardial Infraction II-50

Non ST-Segment Elevation MI II-50

List of Approved Anticoagulants for Non-ST Segment

Elevation Myocardial Infarction II-51

Percutaneous Transluminal Coronary Angioplasty (PTCA) II-51

List of Approved Anticoagulants for Angioplasty Procedures II-52

Heparin Induced Thrombocytopenia (HIT) Indications II-52

HIT Type I II-52

HIT Type II II-52

Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-54

Other Indications II-54

Hemodialysis II-54



Select Anticoagulants in Clinical Development II-55

Anticoagulant Therapies in Development Stage II-56

Idraparinux - Sanofi II-56

0673 - Sanofi II-56

MER-102 II-56

Semuloparin Sodium (AVE 5026) II-56



Mitsubishi Pharma Introduces Argatroban in the UK II-57

Bayer Obtains Canadian Approval for Xarelto in the Treatment

of Deep Vein Thrombosis II-57

Pradaxa Gains Regulatory Approval in Japan for Prevention of

Stroke II-57

Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug II-57

ELIQUIS® Receives Approval in EU in Prevention of VTE II-58

Xarelto Obtains Approval in UK II-58

Xarelto Receives FDA Approval for Prevention of DVT II-58

Eisai Launches Warfarin Granules 0.2% in Japan II-58

Amphastar Receives FDA Approval for ANDA of Enoxaparin Sodium

Injection II-58

Boehringer Ingelheim Obtains EU Approval for Pradaxa in AF II-59

Daiichi Sankyo Introduces Edoxaban Tablets in Japan II-59


4 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs